Stem cell mobilization regimens
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is a gathering point for all stem cell mobilization regimens.
11 regimens on this page
13 variants on this page
|
Stem cell mobilization
These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.
Cyclophosphamide & G-CSF
| back to top |
Regimen #1
| Study | Evidence |
| Oakervee et al. 2005 | Phase II |
Mobilization regimen
- Cyclophosphamide (Cytoxan) 1500 mg/m2 IV once on day 1
- Lenograstim (Granocyte) 263 mcg SC once per day starting on day 4
Stem cell collection begins on day 10 and continues until at least 2 × 106 CD34+ cells/kg are collected.
Regimen #2
| Study | Evidence |
| Royer et al. 2016 | Phase II |
Mobilization regimen
- Cyclophosphamide (Cytoxan) 3000 mg/m2 IV once
- Filgrastim (Neupogen) 10 mcg/kg SC once per day and continued until at least 4 × 106 CD34+ cells/kg are collected
References
- Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. link to original article contains verified protocol PubMed
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains protocol PubMed
Cytarabine & G-CSF
| back to top |
Regimen
| Study | Evidence |
| Abrey et al. 2003 | Phase II |
Mobilization regimen
- Cytarabine (Cytosar) 3000 mg/m2 IV once per day on days 1 & 2
- Filgrastim (Neupogen) 10 mcg/kg SC once per day starting on day 4 and continued until stem cell collection complete
References
- Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. link to original article contains verified protocol PubMed
Cytarabine, Ifosfamide, G-CSF
| back to top |
Regimen
| Study | Evidence |
| Colombat et al. 2006 | Phase II |
Mobilization regimen
- Cytarabine (Cytosar) 1000 mg/m2 IV Q12H on days 1 & 2
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 1 to 3
- Filgrastim (Neupogen) (dose/frequency not specified)
References
- Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. link to original article contains verified protocol PubMed
CYVE & G-CSF
| back to top |
CYVE: CYtarabine, VEpesid (Etoposide)
Regimen
| Study | Evidence |
| Soussain et al. 2001 | Pilot, >20 pts |
| Soussain et al. 2008 | Phase II |
Target collection dose not described; mobilization took place after the first course of CYVE salvage for CNS lymphoma.
Mobilization regimen
- Cytarabine (Cytosar) as follows:
- 2000 mg/m2 IV over 3 hours once per day on days 2 to 5
- 50 mg/m2 IV over 12 hours once per day on days 1 to 5
- Etoposide (Vepesid) 200 mg/m2 IV over 2 hours once per day on days 2 to 5
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting 48 hours after end of chemotherapy
References
- Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. link to original article contains verified protocol PubMed
- Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. link to original article contains verified protocol PubMed
IGEV & Lenograstim
| back to top |
IGEV: Ifosfamide, GEmcitabine, Vinorelbine
Regimen
| Study | Evidence |
| Magagnoli et al. 2007 | Phase II |
Mobilization regimen
- Ifosfamide (Ifex) 2000 mg/m2 IV over 2 hours once per day on days 1 to 4
- Gemcitabine (Gemzar) 800 mg/m2 IV once per day on days 1 & 4
- Vinorelbine (Navelbine) 20 mg/m2 IV once on day 1
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4
Supportive medications
- Mesna (Mesnex) 900 mg/m2 IV at 0, 2, 4 hours after Ifosfamide (Ifex) on days 1 to 4
- Lenograstim (Granocyte) 263 mcg SC once per day on days 7 until at least 3 x 106 CD34+ cells per kg of body weight were collected
Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul.
References
- Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. link to original article contains verified protocol PubMed